MucoLife Therapeutics targets 2027 start for first human trials of inhaled airway treatment
PUBT · 2d ago
Share
Listen to the news
- GU Ventures highlighted portfolio companies Cereno Scientific, MucoLife Therapeutics at Nordic Life Science Days in Stockholm.
- Cereno Scientific develops therapies for rare cardiovascular diseases, lung diseases; runs clinical, preclinical drug programs; listed on Nasdaq First North Growth Market.
- MucoLife Therapeutics is raising capital to target first human clinical studies in 2027 for an inhaled treatment to dissolve airway mucus plugs.
- MucoLife co-founder Thaher Pelaseyed is scheduled to pitch the company on Sept. 9 at the event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GU Ventures AB published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending